Hricik D E, Bartucci M R, Mayes J T, Schulak J A
Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Transplantation. 1992 Nov;54(5):868-71. doi: 10.1097/00007890-199211000-00019.
Lipoprotein profiles were measured before and two months after complete withdrawal of prednisone in 34 kidney and 9 kidney-pancreas transplant recipients subsequently maintained on cyclosporine and azathioprine. Withdrawal of steroid therapy was accompanied by a 17% reduction in total serum cholesterol levels. However, there was a parallel reduction in all other measured lipoprotein concentrations, including an 18% reduction in high-density lipoprotein cholesterol levels. In diabetic recipients of a kidney or kidney-pancreas transplant, the ratio of total to high-density lipoprotein cholesterol was unchanged after steroid withdrawal. In nondiabetic kidney transplant recipients, this ratio actually increased significantly following withdrawal of prednisone. These observations suggest that it is premature to presume that withdrawal of steroid therapy will reduce the cardiovascular risk related to hyperlipidemia in cyclosporine-treated kidney or kidney-pancreas transplant recipients.
在34例肾移植受者和9例肾-胰腺移植受者中检测了脂蛋白谱,这些患者在完全停用泼尼松之前及之后两个月进行检测,随后维持使用环孢素和硫唑嘌呤治疗。停用类固醇治疗后,血清总胆固醇水平降低了17%。然而,所有其他检测的脂蛋白浓度也出现了相应降低,包括高密度脂蛋白胆固醇水平降低了18%。在肾或肾-胰腺移植的糖尿病受者中,停用类固醇后总胆固醇与高密度脂蛋白胆固醇的比值没有变化。在非糖尿病肾移植受者中,停用泼尼松后该比值实际上显著增加。这些观察结果表明,假定停用类固醇治疗会降低环孢素治疗的肾或肾-胰腺移植受者中与高脂血症相关的心血管风险还为时过早。